larotrectinib

a TRK kinase inhibitor

Also Known As:

(3S)-N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; ARRY-470; ARRY470; BAY-2757556; BAY2757556; LOXO-101; LOXO101; N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide; Vitrakvi

Networked: 236 relevant articles (32 outcomes, 43 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - larotrectinib: 236
  - Pyrimidines: 510
    - larotrectinib: 236

Experts

1.	Drilon, Alexander: 19 articles (06/2022 - 01/2017)
2.	Laetsch, Theodore W: 13 articles (01/2022 - 01/2018)
3.	Hong, David S: 11 articles (05/2022 - 05/2017)
4.	Kummar, Shivaani: 9 articles (04/2022 - 01/2018)
5.	Hyman, David M: 9 articles (12/2021 - 01/2017)
6.	Cox, Michael C: 8 articles (11/2019 - 01/2016)
7.	Federman, Noah: 7 articles (01/2022 - 01/2018)
8.	Italiano, Antoine: 6 articles (03/2022 - 11/2020)
9.	DuBois, Steven G: 6 articles (01/2022 - 01/2018)
10.	Pappo, Alberto S: 6 articles (06/2020 - 01/2018)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2020 - "Larotrectinib, a tumour-agnostic TRK inhibitor, has shown remarkable efficacy in a novel "basket" study which has enrolled patients from infants to elderly with different TRK fusion-positive cancers. " 10/01/2021 - "Both are alive, in remission, developing normally and tolerating larotrectinib 15 months later, thus extending the NTRK inhibitor therapeutic spectrum by describing the adjuvant maintenance larotrectinib treatment in children with NTRK fusion-positive cancers associated with high recurrences." 01/01/2020 - "This case shows that larotrectinib could also be effective in cases of NTRK amplification of cancer. " 06/01/2022 - "CONCLUSIONS: Compared with standard of care in metastatic TRK wild-type cancers, larotrectinib is estimated to result in improved LY and QALY outcomes based on parametric extrapolations of intrial survival data. " 01/01/2018 - "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children."
2.	Sarcoma (Soft Tissue Sarcoma) 12/01/2023 - "These results show that larotrectinib is safe and effective in adult patients with TRK fusion sarcomas." 12/01/2023 - "Larotrectinib demonstrated robust and durable responses, extended survival benefit, and a favorable safety profile in adult patients with TRK fusion sarcomas with longer follow-up. " 12/01/2023 - "This subset analysis focuses on the efficacy and safety of larotrectinib in an expanded cohort of adult patients with TRK fusion sarcomas. " 10/21/2023 - "We report a case of sarcoma in a 35-year-old female harboring two STRN-NTRK2 gene fusions, with a good clinical response to first-line larotrectinib treatment. " 01/01/2023 - "Marked Response to Larotrectinib in Pelvic Spindle Cell Sarcoma With Concurrent TPM3-NTRK1 Fusion and CDK4/MDM2 Amplification: A Case Report."
3.	Glioblastoma (Glioblastoma Multiforme) 11/01/2021 - "KEY POINTS: This case highlights the efficacy of the NTRK inhibitor larotrectinib in treating NTRK-rearranged glioblastoma. " 01/01/2020 - "Regression of ETV6-NTRK3 Infantile Glioblastoma After First-Line Treatment With Larotrectinib." 11/01/2021 - "In this article, we report a case of a 26-year-old man with an NTRK2-rearranged isocitrate dehydrogenase-wild-type glioblastoma who showed a robust but temporary response to the NTRK inhibitor larotrectinib. "
4.	Fibrosarcoma 01/01/2021 - "One patient with infantile fibrosarcoma was treated with larotrectinib and achieved complete pathologic remission. " 04/01/2020 - "The Children's Oncology Group has also launched a phase II trial of larotrectinib as a neoadjuvant agent for patients with newly diagnosed infantile fibrosarcoma. " 11/01/2023 - "Our case series supports that larotrectinib may be a therapeutic option for newborn and infant patients with infantile fibrosarcoma, especially in uncommon locations." 01/01/2023 - "Larotrectinib treatment for infantile fibrosarcoma in newborns: a case report and literature review." 01/01/2020 - "A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib."
5.	Colorectal Neoplasms (Colorectal Cancer) 07/01/2022 - "This case represents a marked and durable response to larotrectinib in a patient with deficiency in mismatch repair/MSI-H metastatic colorectal cancer harboring an NTRK fusion, bringing to light the potential for use of larotrectinib in earlier treatment lines in patients, and/or choice of targeted therapy versus immunotherapy in this patient subset." 06/01/2022 - "BACKGROUND: Larotrectinib is approved for patients with metastatic TRK fusion cancers, including differentiated thyroid (DTC), colorectal cancer (CRC), and soft tissue sarcoma (STS). " 06/01/2022 - "The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma." 10/01/2022 - "Aim: To extrapolate clinical trial results to estimate and compare expected progression-free and overall life years (LYs) and quality-adjusted LYs (QALYs) for larotrectinib and entrectinib in patients with colorectal cancer (CRC), soft tissue sarcoma (STS) and brain metastases prior to treatment with larotrectinib or entrectinib. " 01/01/2021 - "A systematic literature review (SLR) was conducted on the clinical outcomes of current histology-based standard of care treatments used in non-small cell lung cancer, colorectal cancer, thyroid cancer, gliomas, soft tissue sarcoma, salivary gland cancer, and infantile fibrosarcoma (7 of the 21 tumor histologies in the larotrectinib trials). "

Related Drugs and Biologics

1.	entrectinib
2.	Phosphotransferases (Kinase)
3.	Tropomyosin
4.	pembrolizumab
5.	Tumor Biomarkers (Tumor Markers)
6.	dostarlimab
7.	Tyrosine (L-Tyrosine)
8.	pemigatinib
9.	ivosidenib
10.	larotrectinib

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Drug Therapy (Chemotherapy)
4.	Neoadjuvant Therapy
5.	Immunotherapy